BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) by Roche is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2024.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCREVUS ZUNOVO is a subcutaneous formulation combining ocrelizumab (a CD20-directed monoclonal antibody) with hyaluronidase, approved September 2024 for CD20+ B-cell malignancies and autoimmune indications. The hyaluronidase enhances subcutaneous delivery, improving patient convenience and potentially reducing infusion burden compared to the intravenous OCREVUS. This represents a formulation advancement within Roche's established CD20 antibody franchise.
Growth
Early-stage commercial launch with growth trajectory; teams will scale launch infrastructure, market access, and field force to capture conversion from IV OCREVUS formulation.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Ocrevus Zunovo for MS: Mixed Methods
Started Jun 2026
150 enrolled
Multiple Sclerosis
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
Started Nov 2018
51 enrolled
Multiple SclerosisRelapsePrimary Progressive Multiple Sclerosis
Career Relevance
Working on OCREVUS ZUNOVO positions you in a high-visibility Roche franchise launch with strong brand legacy and established disease indication familiarity. Growth-stage trajectory offers career momentum in launch execution, conversion strategy, and competitive defense against biosimilars and alternative formats.
Worked on OCREVUS ZUNOVO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.